Preoperative Intravenous Iron and Erythropoietin to Treat Severe Anemia in Patient With Stage 4 Kidney Disease Before Oncologic Surgery: A Case Report

A A Pract. 2020 Jun;14(8):e01234. doi: 10.1213/XAA.0000000000001234.

Abstract

Preoperative treatment of anemia with intravenous iron is inconsistent despite known risks of anemia and allogeneic blood transfusions. Limited research exists on the effectiveness of preoperative intravenous iron for chronic kidney disease (CKD) patients. We discuss a patient with severe anemia from advanced CKD, endometrial cancer, and menometrorrhagia. Her hemoglobin increased more than 2 g/dL after erythropoietin and two 750-mg ferric carboxymaltose infusions 5 weeks before a total abdominal hysterectomy and avoided blood transfusions perioperatively. By raising hemoglobin, preoperative intravenous iron and erythropoietin reduce blood transfusions and consequent risk of future allograft rejection and alloimmunization in potential transplant recipients.

Publication types

  • Case Reports

MeSH terms

  • Administration, Intravenous
  • Anemia / drug therapy*
  • Anemia / etiology
  • Endometrial Neoplasms / surgery
  • Erythropoietin / administration & dosage
  • Erythropoietin / therapeutic use*
  • Female
  • Ferric Compounds / administration & dosage
  • Ferric Compounds / therapeutic use
  • Hemoglobins / analysis
  • Humans
  • Hysterectomy / methods
  • Infusions, Intravenous
  • Iron / administration & dosage
  • Iron / therapeutic use*
  • Kidney Diseases / classification
  • Kidney Diseases / complications
  • Maltose / administration & dosage
  • Maltose / analogs & derivatives
  • Maltose / therapeutic use
  • Middle Aged
  • Preoperative Care / methods*
  • Severity of Illness Index
  • Trace Elements / administration & dosage
  • Trace Elements / therapeutic use
  • Treatment Outcome

Substances

  • Ferric Compounds
  • Hemoglobins
  • Trace Elements
  • Erythropoietin
  • ferric carboxymaltose
  • Maltose
  • Iron